Drug Shortages & Regulatory Affairs: A Silent Compliance Challenge

-

Drug shortages create a significant challenge for the pharmaceutical industry. Supply chain failures trigger regulatory obligations that affect compliance, operations, and patient safety. Regulatory authorities monitor drug availability and enforce strict reporting to protect public health.

Understanding the Impact of Drug Shortages

Drug shortages affect hospitals, pharmacies, and patients. Clinicians face limited treatment options, which may delay therapy. Patients experience interruptions in medication, higher costs, or the need for alternative drugs. Regulatory compliance becomes critical because authorities require timely reporting and mitigation strategies.

Drug Shortages & Regulatory Affairs

Regulatory Responsibilities During Shortages

Regulatory affairs teams handle compliance when shortages occur. Pharmaceutical companies must notify authorities about current or anticipated shortages. Agencies provide clear guidelines on reporting, risk assessment, and communication with healthcare providers. Failure to meet these obligations results in penalties, reputational damage, and risks to patient safety.


Read the Full blog, to know more : 


https://www.linkedin.com/pulse/drug-shortages-regulatory-affairs-silent-compliance-challenge-6b93c

Follow us on :

Facebook: https://www.facebook.com/DDReg/

LinkedIn: https://www.linkedin.com/company/ddregpharma

Twitter: https://x.com/DDRegPharma

Instagram: https://www.instagram.com/ddregpharma/

Comments

Post a Comment

Popular posts from this blog

What is an IMPD? Understanding Its Role in Clinical Trials and Drug Development

-
Image
What is an IMPD? Understanding Its Role in Clinical Trials and Drug Development An Investigational Medicinal Product Dossier (IMPD) is a key document in the clinical trial and drug development process, specifically for drugs or biologics undergoing testing in human clinical trials within the European Union (EU). It serves as a comprehensive report detailing the quality, manufacture, and control of the investigational product. The IMPD is a crucial regulatory submission required by the European Medicines Agency (EMA) or national regulatory bodies to evaluate whether a clinical trial can proceed. Key Components of an IMPD The IMPD includes several sections, providing information that ensures the safety and efficacy of the investigational product. These sections typically cover: Product Description and Composition: The IMPD provides detailed information about the investigational product, including its chemical composition, formulation, and dosage forms. Manufacturing and Control: This...
Read more

GMP Compliance in the Era of Advanced Therapies and Biologics

-
Image
Navigating the New Frontier: GMP Compliance for ATMPs and Biologics The global biopharmaceutical industry is undergoing a transformative shift as Advanced Therapy Medicinal Products (ATMPs)—including gene therapies, somatic cell therapies, and tissue-engineered products—and complex biologics become central to innovation pipelines. With over 1,900 active CGT clinical trials globally as of Q2 2025, according to a report by ARM, these living therapies offer unprecedented clinical benefits. However, their unique nature presents a significant challenge: traditional Good Manufacturing Practice (GMP) frameworks, designed for stable, small molecule drugs, are often not directly applicable. Their development, manufacturing, and distribution demand a fundamentally different approach to compliance. often requiring specialized GMP compliance services . The GMP Paradigm Shift for Living Products What makes ATMPs and biologics so unique from a GMP perspective? Living Products with Inherent Variabili...
Read more

Quasi Drugs: Regulatory & Commercial Considerations for Japan and South Korea

-
Image
Navigating Quasi-Drug Regulations and Market Entry in Japan and South Korea In the dynamic Asia-Pacific market, quasi drugs represent a unique regulatory category that bridges the gap between cosmetics and pharmaceuticals . Particularly in Japan and South Korea, quasi drugs have gained traction for their hybrid benefits offering therapeutic claims while maintaining a relatively simpler regulatory pathway compared to full-fledged drugs.    Understanding the regulatory and commercial landscape of quasi drugs in these two key markets is essential for global companies aiming to enter or expand in East Asia. This article explores the updated guidelines, approval requirements, and commercialization opportunities for quasi drugs in Japan and South Korea.  What Are Quasi Drugs? Quasi drugs are defined as products that have mild pharmacological effects or physiological functions. They may not be as potent as traditional drugs, but they go beyond the scope of general cosmetics. Th...
Read more